A detailed history of Rhumbline Advisers transactions in Grifols Sa stock. As of the latest transaction made, Rhumbline Advisers holds 17,122 shares of GRFS stock, worth $148,961. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,122
Previous 15,914 7.59%
Holding current value
$148,961
Previous $100,000 52.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.28 - $9.38 $7,586 - $11,331
1,208 Added 7.59%
17,122 $152,000
Q2 2024

Aug 01, 2024

BUY
$6.27 - $7.7 $1,899 - $2,333
303 Added 1.94%
15,914 $100,000
Q4 2023

Feb 08, 2024

BUY
$7.71 - $11.56 $52,389 - $78,550
6,795 Added 77.08%
15,611 $180,000
Q3 2023

Nov 09, 2023

BUY
$8.91 - $10.91 $2,494 - $3,054
280 Added 3.28%
8,816 $80,000
Q2 2023

Aug 08, 2023

BUY
$7.14 - $9.29 $60,947 - $79,299
8,536 New
8,536 $78,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.91B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.